Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status

Lorlatinib treatment should be positively considered even for patients with ALK‐positive NSCLC with severe neurocognitive disturbance and poor performance status due to CNS metastases, including leptomeningeal carcinomatosis.

Detalles Bibliográficos
Autores principales: Taketa, Tomoyo, Nakamura, Takahito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077276/
https://www.ncbi.nlm.nih.gov/pubmed/33936630
http://dx.doi.org/10.1002/ccr3.3927
_version_ 1783684849734778880
author Taketa, Tomoyo
Nakamura, Takahito
author_facet Taketa, Tomoyo
Nakamura, Takahito
author_sort Taketa, Tomoyo
collection PubMed
description Lorlatinib treatment should be positively considered even for patients with ALK‐positive NSCLC with severe neurocognitive disturbance and poor performance status due to CNS metastases, including leptomeningeal carcinomatosis.
format Online
Article
Text
id pubmed-8077276
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80772762021-04-29 Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status Taketa, Tomoyo Nakamura, Takahito Clin Case Rep Case Reports Lorlatinib treatment should be positively considered even for patients with ALK‐positive NSCLC with severe neurocognitive disturbance and poor performance status due to CNS metastases, including leptomeningeal carcinomatosis. John Wiley and Sons Inc. 2021-02-11 /pmc/articles/PMC8077276/ /pubmed/33936630 http://dx.doi.org/10.1002/ccr3.3927 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Taketa, Tomoyo
Nakamura, Takahito
Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status
title Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status
title_full Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status
title_fullStr Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status
title_full_unstemmed Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status
title_short Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status
title_sort efficacy of lorlatinib treatment in alk rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077276/
https://www.ncbi.nlm.nih.gov/pubmed/33936630
http://dx.doi.org/10.1002/ccr3.3927
work_keys_str_mv AT taketatomoyo efficacyoflorlatinibtreatmentinalkrearrangementlungcancerwithseveresymptomaticcentralnervoussystemmetastasesandpoorperformancestatus
AT nakamuratakahito efficacyoflorlatinibtreatmentinalkrearrangementlungcancerwithseveresymptomaticcentralnervoussystemmetastasesandpoorperformancestatus

Ejemplares similares